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Abstract
Purpose To describe prescribing of medicines in primary care in the last year of life in patients with dementia.
Method A retrospective cohort analysis in UK primary care using routinely collected data from the Clinical Practice Research
Datalink. Number of medications and potentially inappropriate medication prescribed one year prior to, and including death, was
ascertained.
Results Dementia patients (n = 6923) aged 86.6 ± 7.3 years (mean ± SD) were prescribed 4.8 ± 4.0 drugs 1 year prior to death,
increasing to 5.6 ± 4.0 2months prior, before falling to 4.9 ± 4.1 at death. One year prior to death, 50% of patients were prescribed
a potentially inappropriate medication, falling to 41% at death. Cardiovascular medications were the most common, with
decreases in drug count only occurring in the last month prior to death. Prescriptions for gastrointestinal and central nervous
systemmedication increased throughout the year, particularly laxatives/analgaesics, antidepressants and hypnotic/antipsychotics.
Women (vs. men) and patients with Alzheimer’s (vs. vascular dementia) were prescribed 4.7% (95% CI 2.3%–7%) and 14.6%
(11.7–17.3%) fewer medications, respectively. Prescribing decreased with age and increased with additional comorbidities.
Conclusions Dementia patients are prescribed high levels of medication, many potentially inappropriate, during their last year of
life, with reductions occurring relatively late. Improvements tomedication optimisation guidelines are needed to inform decision-
making around deprescribing of long-term medications in patients with limited life-expectancy.
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Abbreviations
CPRD Clinical Practice Research Datalink
GP General practice
BNF British National Formulary
ZIP Zero-inflated Poisson
Background
Dementia is a growing challenge for primary health care ser-
vices, with an estimated 7% of over 65 s affected [1], and
numbers likely to increase given our ageing population.
Polypharmacy, the co-prescription of multiple drugs, is com-
mon [2, 3] and a particular concern amongst patients with
dementia. Memory loss and impaired cognitive function
may lead to adherence problems with complex medication
regimens, and patients may have difficulty in communicating
problems related to adverse drug effects [4]. There is also
evidence that inappropriate prescribing is frequent [5], and
altered pharmacokinetics and pharmacodynamics may make
the adverse consequences more serious in this older,
multimorbid population.
These issues are especially concerning in the context of
limited life expectancy, given the time required for demonstra-
ble benefits to be achieved with certain medications [6, 7].
Furthermore, the evidence for clinical effectiveness of most
drugs comes from randomised controlled trials which exclude
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individuals with dementia or at the end of life [8], so the
balance of risks and benefits may be less favourable than in
the general population. Current evidence of prescribing prac-
tices in dementia patients is predominantly from nursing home
residents [9–11] or cross-sectional studies [12–14]. There has
been limited study of changes in medication use during the
last phases of life in patients with dementia in the community.
The aim of this study was to describe patterns of
polypharmacy in the last year of life amongst adults with a
diagnosis of dementia and examine variations in prescribing
by demographic and clinical factors.
Method
Study population
We conducted a descriptive analysis using routinely collected,
anonymised, UK primary care health records from the Clinical
Practice Research Datalink (CPRD) [15]. Approval for the
study was granted by the CPRD Independent Scientific
Advisory Committee (Protocol reference 15_106R). The
CPRD is a large database containing electronic medical health
records of over 5 million active patients from approximately
650 general (family) practices (GP) and is considered a repre-
sentative sample of the general UK population [15]. Coded
data available for each patient include clinical diagnoses and
detailed information on drugs prescribed [16, 17].
For this study, patients who had died between May 2013
and April 2014 and had a diagnosis of dementia at or before
death were identified using the electronic GP medical records
and linked Office of National Statistics death registry. A de-
mentia diagnosis was defined using Read codes, a standard
clinical coding classification used in UK primary care [18], for
any relevant clinical diagnosis in the GP medical record or a
relevant ICD-10 code in the death registry (Appendix 1).
Measurements
Polypharmacy was ascertained at death (i.e. an ongoing pre-
scription on the date of death) and at 2 weeks, 1, 2, 4, 6, 9 and
12 months prior to death, from primary care records. These
time intervals were based on pragmatism and clinical judge-
ment. Almost all prescriptions issued by a GP to a patient will
be captured by CPRD as prescribing is conducted almost ex-
clusively electronically. Prescription length was calculated by
dividing drug quantity by number of daily doses; where miss-
ing, imputed from the population average for that drug
(Appendix 2). Drugs were categorised according to the
British National Formulary (BNF) [19]. Palliative care medi-
cat ions were also ident i f ied (Appendix 3) [20] .
Appropriateness of medications was classified using a previ-
ously published list developed using a Delphi consensus
approach for adults with advanced dementia [7]. For this anal-
ysis, medications were defined as never appropriate and rarely
appropriate (Appendix 3). In addition, prescribing safety indi-
cators [21] taken from the Royal College of General
Practitioners (RCGP) indicator list [22] and used in the
PINCER trial [23] and a general measure of potentially haz-
ardous prescribing (≥ 1 of 19 indicators [P1–P19]) was de-
rived for each time point. Prescriptions were limited to
enteral-administered drugs, as the duration of individual pre-
scriptions can be determined more reliably; these accounted
for three-quarters of all medications in this population. For the
analysis of palliative medications, we also included injectable
drugs.
A count of all ongoing prescriptions of unique drug sub-
stances at each time point was derived. Counts were also de-
rived for selected BNF chapters (most frequent enteral-
administered prescriptions identified by Guthrie et al. [24])
and inappropriate medication. Throughout the paper, the term
polypharmacy is used to indicate multiple concurrent medica-
tions, without implying appropriateness of medication or any
particular minimum quantity.
A list of 37 physical and mental long-term conditions
established by clinical expert consensus [25–27] was used to
ascertain comorbidity status in participants at 1 year prior to
death. An unweighted count of clinical conditions was de-
rived, and a seven-category measure, grouping ≥ 6 conditions,
was created.
Dementia subtype (vascular, Alzheimer’s disease, other
and unspecified) and care home status during the last year of
life were ascertained using clinical Read codes (Appendices 1
and 4, respectively). Analysis of dementia subtype was re-
stricted to patients with a recorded diagnosis of vascular de-
mentia or Alzheimer’s.
Statistical analysis
Counts and averages were used to describe changes in the
number of prescriptions over time. Zero-inflated Poisson
(ZIP) regression models were fitted to investigate differences
in the number of prescriptions at each time point and across
different demographic and clinical factors. Robust standard
errors were used which allowed for correlations across differ-
ent time points within individual patients (i.e. multiple pre-
scription counts). A ZIP regression is a two-stage process, first
predicting whether individuals had any prescriptions using a
logit regression model, and secondly, a Poisson model to pre-
dict the rate of prescriptions amongst patients prescribed med-
ication; the final output combining the twomodels. Number of
days prior to death was included as a covariate in the logit and
Poisson regression model, and univariable Poisson regression
models were used to investigate associations with gender, age,
dementia subtype, care home status and multimorbidity score.
Estimates from the models are presented in terms of the
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expected relative difference (RD) and 95% confidence inter-
vals (CI) in number of medications prescribed per unit in-
crease in the exposure of interest.
Interactions between each exposure and number of days
until death were examined using a likelihood ratio test. For
age and comorbidity, non-linear associations with prescription
count were investigated and the most appropriate, as deter-
mined using likelihood ratio tests, is presented. Wald tests
were used to test whether the association changed over time.
All analyses were conducted using Stata 14, and all statis-
tical tests were two sided.
Results
A total of 6923 patients (mean age 86.6 ± 7.3 years, 64%
female) with a diagnosis of dementia died during the study
period (Table 1). Patients with vascular dementia had a mean
of 4.0 ± 2.2 additional comorbidities, of which 1.9 ± 1.3 were
cardiovascular disease (CVD) related, compared with 2.9 ±
2.0 comorbidities (1.1 ± 1.1 CVD related) for those with
Alzheimer’s.
Of all products prescribed in the study period (n =
219,543), 69.2% (n = 151,975) were enteral administered.
Remaining products included topical (11.9%, n = 26,019),
non-pharmacological (5.6%, n = 12,208), injected (4.9%,
n = 10,724), inhaled (2.1%, n = 4,532), administered to ears,
eyes, or nose (1.9%, n = 4,133) and unknown (4.2%, n =
9,216).
Changes in overall prescribing over time
On average, dementia patients were prescribed 4.8 ± 4.0
enteral-administered drugs at baseline (1 year prior to death),
increasing to 5.6 ± 4.1 1 month prior to death, falling to 4.9 ±
4.1 prescriptions ongoing on the date of death (Fig. 1). In the
ZIP models, the overall number of drugs prescribed increased
by 3.0% (95% confidence interval 1.5 to 4.5%) between the
baseline and 1 month prior, with prescribing falling by 4.3%
(− 5.9 to − 2.6%) at death compared with 1 year prior
(Appendix 5).
Palliative medication prescriptions (both enteral adminis-
tered and injections) increased across the year, with a sharp
rise from 0.5 ± 1.1 drugs 2 weeks prior to death to 1.2 ± 2.1 at
death (Fig. 1), opioids being the most frequently prescribed.
On the date of death, 41.0% (n = 2,838) of patients had at least
one prescription for a palliative medication. In the ZIP model,
the increase in palliative medication prescriptions at death
represented nearly a 5-fold (474.3%; 418.0 to 538.4%) in-
crease compared to 1 year prior.
Prescribing for specific therapeutic areas
Stratified by BNF chapter, cardiovascular medications were
the most frequently prescribed drugs throughout the last year
of life, and musculoskeletal the least (Fig. 2a). On average,
patients were prescribed 1.7 ± 2.0 cardiovascular drugs at
baseline, with 1.3 ± 2.0 continuing to be prescribed at death,
representing a 17.4% (− 15.1 to − 19.7%) fall (Fig. 2b). Levels
of angiotensin-converting enzyme inhibitors, angiotensin II
receptor blockers, calcium-channel blocker, beta-blockers
and diuretics (ABCD medication) remained constant (≈0.8
drugs) until 1 month prior to death.
There were increases in gastrointestinal medication and
drugs affecting the central nervous system (CNS) over the
12 months prior to death. On average, prescriptions in-
creased from 0.8 ± 1.0 to 0.9 ± 1.1 and 1.2 ± 1.5 to 1.5 ±
1.6 at 12 months and 1 month prior to death for gastrointes-
tinal and CNS medication, respectively. After accounting for
correlation over time, the number of gastrointestinal and
CNS medication increased by 6.5% (1.7 to 11.6%) and
8.4% (5.1 to 11.9%), respectively, between 12 months and
1 month prior to death (Appendix 6). Increases were ob-
served for laxatives and indigestion medication (Fig. 2c),
and for analgaesics, antidepressants and hypnotics and anti-
psychotics (Fig. 2d).
Table 1 Frequency of selected characteristics of participants
n Mean
(SD) (%)
Gender Men 2513 36.3
Women 4410 63.7
Age at death (years) 6923 86.6 (7.3)
Dementia subtype a Vascular 1940 32.3
Alzheimer’s 1760 29.3
Other 85 1.4
Unspecified 2220 37.0
Comorbidity 1 year prior to death
(excluding dementia) b
Mean (SD) 6923 3.3 (2.2)
0 756 10.9
1 815 11.8
2 1011 14.6
3 1209 17.5
4 1173 16.9
5 869 12.6
6+ 1090 15.7
Lives in a care home No 5084 73.4
Yes 1839 26.6
SD, standard deviation; IQR, interquartile range
a Dementia subtypes other includes dementia associated with Parkinson’s,
Huntington’s, and Picks Disease, HIV/AIDS, and alcohol abuse. Two
hundred forty-one patients diagnosed with vascular and Alzheimer’s de-
mentia, the most frequent diagnosis was used
b Comorbidity list includes 37 chronic conditions
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Prescribing of inappropriate medications
One year prior to death, half (49.9%) of the patients were
prescribed at least one drug considered inappropriate in severe
dementia, dropping to 41.2% at death. Average number of
inappropriate drugs fell from 1.0 ± 1.2 at 4 months to 0.7 ±
1.1 at death (Fig. 1). There was little change in prescribing of
inappropriate medication until 1 month prior to death, when
there was a 4.3% (− 0.6 to − 7.8%) decrease, with an even
greater decrease of 11.2% (− 7.1 to − 15.1%) at death, com-
pared with 1 year prior. Lipid-lowering agents and
bisphosphates were the most commonly prescribed never
and rarely appropriate medication, respectively (Fig. 3).
Potentially hazardous prescribing followed a similar pattern,
with over 16.4% of participants prescribed at least one
12 months prior to death, falling to 7.3% at death (Fig. 3a).
Factors that influence differences in prescribing
The relative differences in prescribing between key demo-
graphic and clinical factors are presented in Fig. 4. Women,
older patients and those with Alzheimer’s were generally pre-
scribed fewer drugs overall compared with men (RD = −
4.7%; − 2.3 to − 7.0%), younger patients (oldest vs. youngest
quartile, RD = − 15.6%; − 12.5 to − 18.5%) and those with
vascular dementia (RD = − 14.6%; − 11.7 to − 17.3%). The
magnitude of differences in overall prescribing between de-
mentia subtypes decreased over time (Alzheimer’s vs. vascu-
lar − 16.0% (− 19.3 to − 12.5%) at 1 year; − 10.3% (− 14.2 to
− 6.2%) at death; p = 0.002). Similar patterns were found for
inappropriate prescribing (data not shown). There was no
overall difference in prescribing between care home residency
status, although inappropriate prescribing was lower in pa-
tients living in care homes compared with those not (RD =
− 17.4%; − 12.3 to − 22.3%).
The number of drugs prescribed across the year varied by
comorbidity status (p value < 0.001; Fig. 4d). Patients with a
higher number of comorbidities experienced little change in
the number of prescriptions in the last year of life, until near
death when prescribing decreased. In contrast, prescribing in-
creased amongst patients with fewer comorbidities.
Discussion
Findings from this study of electronic health records indicate
that there are high levels of prescribing amongst dementia
patients during their last year of life, with a significant propor-
tion of the population prescribed an inappropriate medication
throughout the year, with nearly half having such a prescrip-
tion 2 weeks prior to death. The overall number of drugs
increased over the last 12 months, and reductions were
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Fig. 1 Average (mean) number of prescriptions in the last year of life of
dementia patients, stratified by appropriate prescribing All prescriptions
restricted to enteral administered drugs. Never appropriate medication
include lipid-lowering medication, cholinesterase inhibitors, antiplatelet
agents (excluding aspirin), memantine, hormone antagonists,
antioestrogen, leukotriene receptor antagonists, cytotoxic chemotherapy,
sex hormones and immunomodulators. There were no prescriptions of
antioestrogen, leukotriene receptor antagonists, cytotoxic chemotherapy,
sex hormones and immunomodulators in the last year of life amongst the
study population. Rarely appropriate medication includes bisphosphonates,
warfarin, digoxin, bladder relaxants, tamsulosin, antiandrogens, alpha
blockers, antiarrhythmics, antispasmodics, mineralocorticoids, clonidine,
hydralazine and heparin. There were no prescriptions of clonidine,
hydralazine and heparin in the last year of life amongst the study population
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generally only observed relatively close to death. In particular,
a high level of cardiovascular drugs was consistently pre-
scribed until the final month, whilst gastrointestinal and
CNS medication increased.
Strengths and limitations
To our knowledge, this is the first general population study to
investigate changes in the number and types of medication
prescribed in primary care during the last year of life amongst
patients who died with dementia. Combining primary care
health records with national death registration data helped
maximise identification of cases, providing a good represen-
tation of the UK population. Due to the ubiquitous nature of
electronic prescribing in UK primary care, CPRD also pro-
vides full and detailed information on a patient’s prescribing
history in primary care. Despite these strengths, several limi-
tations are worth consideration, including potential misclassi-
fication and drug indication, which are common to most
studies using these types of routine clinical data. Information
on prescribing outside of primary care, including in secondary
care and “over the counter” were not available. Detailed clin-
ical information on dementia diagnosis and progression, such
as age at diagnosis and severity, is not captured, as demon-
strated by the high level of missing information on dementia
subtype. Nevertheless, the underlying pathogenesis was still
available in around two-thirds of cases. The definition of in-
appropriate medication was drawn from a list developed for
advanced dementia, despite lack of information about severi-
ty. A recent large cohort study found that patients who died
with a dementia diagnosis, only one-quarter were at the severe
stage of the illness [28]; thus, the appropriateness of such a list
may be limited. However, there is no agreed alternative defi-
nition of inappropriate prescribing for dementia patients in the
end-of-life context, and our choice was thus a pragmatic one
although nevertheless clinically relevant. We compared find-
ings using an alternative, general measure of potentially haz-
ardous prescribing, and found levels to be three times higher
Fig. 2 Average (mean) number of enteral prescriptions in the last year of
life of dementia patients, stratified by BNF chapter. a Selected BNF
chapters; b Indigestion BNF sub-chapter 1.1 & 1.3, laxatives BNF sub-
chapter 1.6, other includes all remaining chapter 1 sub-chapters. cABCD
BNF sub-chapter 2.5.5.1/2, 2.4, 2.6.2 & 2.2.1-4/8, Anti-coagulants, anti-
platelets BNF subchapter 2.8/9, Lipid-lowering BNF sub-chapter 2.12,
other includes all remaining chapter 2 sub-chapters. d Antidepressants
BNF sub-chapter 4.3, Analgesia BNF sub-chapter 4.7, Hypnotics and
anti-psychotics BNF sub-chapter 4.1/2, Dementia medication BNF sub-
chapter 4.11, other includes all remaining chapter 4 sub-chapters. BNF
British National Formulary, ABCD angiotension-converting enzyme
inhibitors, angiotensin II receptor antagonists, beta-adrenoceptor
blocking drugs, calcium-channel blockers, Diuretics. All, never and
rarely appropriate medication include enteral-administered drugs
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CI: confidence intervals
Fig. 4 Average (mean) and relative difference (RD) in the number of
enteral prescriptions in the last year of life of dementia patients by demo-
graphic and clinical factors. CI, confidence intervals. Zero-inflated
Poisson regression models were fitted, and correlated standard errors at
the patient level were used to account for the multiple measures (i.e.
prescription counts) within individuals. Relative difference presented rep-
resents the average difference in drug count for a unit increase in the
exposure over the year period. For age and multimorbidity, continuous
measures were used. The reference for A. gender was men, and for C.
dementia subtype was vascular dementia. *Evidence of statistical inter-
action between exposure and time from death (p value < 0.001). All
medication includes enteral-administered drugs. A list of 37 physical
andmental chronic conditions was used to ascertain multimorbidity status
in participants 1 year prior to death. The condition list was based on work
by Barnett et al. and clinical consensus [13, 14]
a b c
Fig. 3 Proportion of dementia patients in the last year of life prescribed at
least one inappropriate medication, and average (mean) number of
prescriptions, stratified by appropriate prescribing. AP appropriate
prescription, PHP potentially hazardous prescription. All prescriptions
restricted to enteral administered drugs. Never appropriate medication
include lipid-lowering medication, cholinesterase inhibitors, antiplatelet
agents (excluding aspirin), memantine, hormone antagonists,
antioestrogen, leukotriene receptor antagonists, cytotoxic chemotherapy,
sex hormones and immunomodulators. There were no prescriptions of
antioestrogen, leukotriene receptor antagonists, cytotoxic chemotherapy,
sex hormones and immunomodulators in the last year of life amongst the
study population. Rarely appropriate medication includes bisphosphonates,
warfarin, digoxin, bladder relaxants, tamsulosin, antiandrogens, alpha
blockers, antiarrhythmics, antispasmodics, ineralocorticoids, clonidine,
hydralazine and heparin. There were no prescriptions of clonidine,
hydralazine and heparin in the last year of life amongst the study
population. Potentially hazardous prescribed is a composite measure of
prescribing safety indicators P1-P19 [21]
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in our dementia study population than those observed in the
older general population [21]. Similar conclusions from these
two analyses highlights that there are important opportunities
to potentially improve prescribing in this population. Finally,
our cohort was defined by death, and it is therefore not possi-
ble to comment on how prescribing varies with prospective
assessment of life expectation, either by clinical judgement
(e.g. the “surprise question” [29]) or objective risk assessment
(e.g. QMortality [30]). This would be an important direction
for future work.
Comparison with existing literature
This study supports previous findings of high levels of pre-
scribing amongst dementia patients and the ongoing use of
inappropriate medication in this population. The number of
medications prescribed was comparable with the existing lit-
erature (range, 4 to 5.4) [2, 5, 12, 31]. Consistent with previ-
ous longitudinal studies [9–11, 32], our results indicate that
dementia patients experience an overall increase in prescrib-
ing in the last year of life. Levels of inappropriate prescribing
were similar to those reported elsewhere. A US study of nurs-
ing home residents with advanced dementia found half were
prescribed at least 1 drug with questionable benefit [33].
Based on the RCGP safety indicators, hazardous prescribing
appears to have declined over the 12 months reflecting imple-
mentation of appropriate improvements in prescription regi-
men, although rates were still considerably higher than the
general population [21]. Furthermore, inappropriate prescrib-
ing quantified by specific therapeutic classes persisted until
relatively late in life.
As indicated elsewhere [34], older patients had lower levels
of prescribing compared with younger patients, suggesting
physicians may be considering limited life expectancy and
withholding treatments in the older age groups. Women were
prescribed fewer drugs overall, with fewer high-risk medica-
tions compared with men. This may, in part, be accounted for
by women being older and having fewer comorbidities. In the
literature, there are mixed results relating to gender differences
in prescribing, in particular with relation to inappropriate med-
ication [9, 31]; this probably reflects variations in dementia
severity and definitions of inappropriate prescribing between
studies.
As in the general population, we found comorbidity to be
associated with higher levels of prescribing [5, 12, 13, 35].
Dementia patients with higher levels of comorbidity experi-
enced little change in their medication in their last year of life,
whilst those with fewer comorbidities were prescribed more
medications. This difference reflects low levels of medication
at baseline amongst patients with no other conditions, with
increases probably indicating health deterioration and pre-
scribing related to symptom management.
Implications for research and/or practice
Findings from this study indicate that dementia patients re-
ceive considerable numbers of medications in their last year
of life, many of which are considered inappropriate. Although
rates of potentially hazardous prescribing did decline some-
what, these observations nevertheless support the need for
improved medication optimisation strategies for patients
experiencing polypharmacy [36]. Furthermore, they demon-
strate that, outside of the palliative care setting, withdrawal or
reduction of medications is uncommon. In part, this reflects
the difficulties of predicting death 12 months in advance; cli-
nicians may be reluctant to reduce potentially life-prolonging
treatment in the face of considerable uncertainty around life
expectancy, and indeed may not consider deprescribing in the
first place if the patient is not obviously dying. The findings
may also reflect the lack of a strong evidence base or any
clinical guidelines to inform decisions around deprescribing
of long-term medications [37].
Clinicians and policymakers alike need to ensure that med-
ication optimisation remains a prominent aspect of clinical
management for patients with dementia towards the end of
life. There is also a pressing need to develop better evidence
to support improved prescribing for these patients. This
should include enhanced trial data for the effectiveness of
long-term medications, improved methods for the identifica-
tion of individuals with limited life expectancy and better
medication optimisation strategies tailored to the specific
needs of this vulnerable population.
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